Date: 03/11/2025

• Groundbreaking data from first whole body application of QRX003 underscores potential efficacy
• Transformational improvement in disease state after just 2 weeks of treatment
• Clear visual evidence of skin healing observed
• Improvement has eliminated need for previously required medications
• Patient is now experiencing zero nightly sleep disturbance for the first time
• No adverse events reported from whole body treatment

Read the full press release here https://www.globenewswire.com/news-release/2025/02/27/3033744/0/en/Quoin-Pharmaceuticals-Announces-Highly-Positive-Whole-Body-Clinical-Data-from-Ongoing-Pediatric-Netherton-Syndrome-Study.html